Insider Cluster (2 insiders) ·Filed Apr 1, 2026

SYRE

Spyre Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $703K total
Actionable Insight ▼ Bearish

While the dollar amount is not large relative to market cap, the coordinated exit by two top executives immediately after exercising options may signal lack of near-term conviction. Traders should monitor for absence of offsetting buys and watch for upcoming earnings or clinical updates that could explain timing.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
SYRE ▲ +84.38% at T+60d
SHORT call ✗ call lost -84.38% · α vs SPY -71.00% · entry $48.90 → $90.16
Entry anchored
Mar 31, 03:59 PM ET
via exchange tick
T+1d
-2.70%
call +2.70% · α +2.78%
$47.58
settled 6mo ago
T+5d
+5.87%
call -5.87% · α -2.10%
$51.77
settled 6mo ago
T+20d
+47.01%
call -47.01% · α -37.29%
$71.89
settled 5mo ago
T+60d
+84.38%
call -84.38% · α -71.00%
$90.16
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two key executives at Spyre Therapeutics — the CFO and CMO — sold a combined $703K in open-market transactions on April 1, 2026, following derivative exercises. The sales represent a modest but notable insider selling cluster involving C-suite leadership.

Key Financial Metrics

Direction
selling
Total Value
$703.0K
Insiders
2

Key Facts

  • CFO Burrows Scott L sold 6,200 shares for $305,102 at $49.21 per share.
  • CMO Sloan Sheldon sold 7,958 shares for $397,900 at $50.00 per share.
  • Both executives also exercised in-the-money derivatives prior to selling, with no additional open-market purchases.
  • Total open-market sale value: $703K, representing ~0.019% of $3.7B market cap — modest in size but significant due to C-suite participation.
  • No insider buying was reported in the cluster.

Financial Impact

$703,000 in net insider selling by CFO and CMO

insider sentimentshareholder confidence

Risk Factors

  • Perception of insider pessimism given no reinvestment or retention of shares post-exercise.
  • Potential for negative market reaction due to C-suite selling, especially if no clear rationale is disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SYRE-1775266236001
26 reports for SYRE
Performance horizon
75% Hit rate 9 of 12 directional calls best @ T+60▲ +54.27%Apr 13, 2026
Filters
Rows
Reports for SYRE — sortable, filterable
TypeNow
Sep 4, 2026
28d ago
Insider Cluster
BEARISH ★ 5/10
$88.98 $90.80▼ −2.05%▼ −3.25%$93.19 (−4.73%)
Aug 11, 2026
7w ago
Insider Cluster
BEARISH ★ 5/10
$102.74 $107.82▼ −4.94%▼ −5.35%$93.19 (+9.30%)
Aug 6, 2026
8w ago
Insider Cluster
BEARISH ★ 5/10
$103.42 $101.85▲ +1.52%▲ +2.73%$93.19 (+9.89%)
Jul 3, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$86.63 $98.75▲ +13.99%▲ +13.06%$93.19 (+7.57%)
Jun 27, 2026
13w ago
Insider Cluster
BEARISH ★ 7/10
$90.16 $88.74▲ +1.57%▲ +2.96%$93.19 (−3.36%)
Jun 26, 2026
14w ago
S-3ASR
NEUTRAL ★ 5/10
$90.16 $88.74▼ −1.57%▼ −2.96%$93.19 (+3.36%)
Jun 24, 2026
14w ago
Insider Cluster
BEARISH ★ 7/10
$86.24 $88.89▼ −3.07%▼ −1.37%$93.19 (−8.06%)
Jun 15, 2026
15w ago
8-K
BULLISH ★ 7/10
$83.58 $100.32▲ +20.03%▲ +21.41%$93.19 (+11.50%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$80.79 $88.34▲ +9.35%▲ +8.67%$93.19 (+15.35%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$80.77 $87.49▲ +8.32%▲ +7.89%$93.19 (+15.38%)
Showing 10 of 26

US Market Status

Market Closed — Opens Mon (65h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 4, 2026